首页>
外国专利>
PLASMAGLUCOSYLCERAMIDDEFIZIENZ ALS RISIKOFAKTOR FÜR THROMBOSE UND MODULATOR VON ANTICOAGULANT PROTEIN C
PLASMAGLUCOSYLCERAMIDDEFIZIENZ ALS RISIKOFAKTOR FÜR THROMBOSE UND MODULATOR VON ANTICOAGULANT PROTEIN C
展开▼
机译:血浆葡糖苷神经酰胺缺乏症是抗凝蛋白C的血栓形成和调节剂的危险因素。
展开▼
页面导航
摘要
著录项
相似文献
摘要
The present invention has determined that exogenously added glycosylceramide (GlcCer) and other neutral glycolipids such as the homologous Glc-containing globotriaosylceramide (Gb3Cer), dose-dependently prolonged clotting times of normal plasma in the presence but not absence of APC:protein S, indicating GlcCer or Gb3Cer can enhance protein C pathway anticoagulant activity. In studies using purified proteins, inactivation of factor Va by APC:protein S was enhanced by GlcCer alone and by GlcCer, globotriaosylceramide, lactosylceramide, and galactosylceramide in multicomponent vesicles containing phosphatidylserine and phosphatidylcholine. Thus, the present invention provides neutral glycolipids such as GlcCer and Gb3Cer, as anticoagulant cofactors that contribute to the antithrombotic activity of the protein C pathway. The present invention has also determined that a deficiency of plasma GlcCer is a risk factor for thrombosis. Methods are provided to determine individuals at risk for thrombosis, methods of treatment as well as methods of screening for antithrombotic factors from neutral glycolipids.
展开▼